MENU
OCT 22, 2020

OncomineWorld Autumn: A virtual NGS education meeting - We are back!


OncomineWorld Autumn presents an all-new opportunity to learn about the latest developments in cancer genomic profiling. If you attended our May event, you were one of over 3,000 dedicated professionals who came together to advance understanding of and exchange knowledge about precision oncology research. We're back with more great programming on October 22, 2020.

What’s new to OncomineWorld Autumn?

  • New live presentations from experts in the field in 3 live sessions to accommodate our global audience. There will be an "oncology biomarkers testing education track" as well as new Genexus System users sharing their experiences, and much more.
  • Live Demos of the new Ion Torrent Genexus System, streamed live from a Thermo Fisher Scientific lab
  • Possibility for video chats and meetings with other participants and our experts
  • New content in the Precision Oncology Hall, with all about why and how genomic profiling for precision oncology should be done in-house, locally and close to patients

In this virtual NGS education meeting you will be able to:

  • Earn CE credits from on-demand or live presentations from leading NGS users on topics such as comprehensive genomic profiling (CGP), the future of precision oncology biomarkers testing, personal experiences with different NGS products and solutions, and much more.
  • Explore our virtual laboratories to learn about the new world of easy and fast NGS – the Genexus System - and many NGS application areas, including emerging NSCLC biomarkers, liquid biopsy, and hemato- oncology research.
  • Visit the Precision Oncology Hall to access videos, posters, and more on the future potential of NGS to enable access to precision medicine for more patients
  • See the latest research by Thermo Fisher Scientific in the Poster Hall

We hope you will enjoy and benefit from this meeting. We are open to any questions or feedback before, during, and after the live event.

 

Sincerely,

Your Thermo Fisher Scientific Oncology NGS team

 

For Research Use Only. Not for use in diagnostic procedures.


Speakers

Show Resources
Agenda
  • LIVE DEMO: The Ion Torrent Genexus System
    OCT 22, 2020 2:10 PM PDT
    LIVE DEMO: The Ion Torrent Genexus System
    Andrew Hutchison
    Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
    OCT 22, 2020 1:35 PM PDT
    Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
    Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
  • Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
    OCT 22, 2020 1:15 PM PDT
    Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
    Craig Mackinnon, MD, PhD
    Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
  • Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
    OCT 22, 2020 12:25 PM PDT
    Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
    Megan S. Lim, MD, PhD
    Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
  • Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
    OCT 22, 2020 12:05 PM PDT
    Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
    Carmen Kletecka, MD, FCAP, FASCP
    Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
  • LIVE DEMO: The Ion Torrent Genexus System
    OCT 22, 2020 5:15 PM CEST
    LIVE DEMO: The Ion Torrent Genexus System
    Andrew Hutchison
    Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
    OCT 22, 2020 4:40 PM CEST
    First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
    Ines Raineri, MD
    Staff Pathologist, Institute for Pathology medica AG
  • NGS evolution in Solid Tumours, from S5-XL to Genexus
    OCT 22, 2020 4:20 PM CEST
    NGS evolution in Solid Tumours, from S5-XL to Genexus
    Javier Hernandez-Losa, PhD
    Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
  • Next Generation rEvolution in Myeloid Neoplasms clinical research
    OCT 22, 2020 3:35 PM CEST
    Next Generation rEvolution in Myeloid Neoplasms clinical research
    Giada Rotunno, PhD
    Research Scientist, University of Florence
  • NGS for precision oncology in solid tumors: from research to clinical practice
    OCT 22, 2020 3:05 PM CEST
    NGS for precision oncology in solid tumors: from research to clinical practice
    Nicola Normanno, MD
    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • LIVE DEMO: The Ion Torrent Genexus System
    OCT 22, 2020 2:10 PM SGT
    LIVE DEMO: The Ion Torrent Genexus System
    Andrew Hutchison
    Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Latest Developments with the Genexus System
    OCT 22, 2020 1:35 PM SGT
    Latest Developments with the Genexus System
    Dr. Jose Luis Costa
    Medical Director, Thermo Fisher Scientific
  • OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
    OCT 22, 2020 1:15 PM SGT
    OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
    Ahwon Lee, MD, PhD
    Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
  • The role of PARPis and HRD testing in advanced ovarian cancer
    OCT 22, 2020 12:25 PM SGT
    The role of PARPis and HRD testing in advanced ovarian cancer
    Natalie Ngoi, MBBS, MMed, MRCP
    Associate Consultant, National University Cancer Institute, Singapore
  • Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
    OCT 22, 2020 12:05 PM SGT
    Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
    Aaron Tan, PhD
    Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
  • Asia Pacific Session 1
    • Part 1: NGS in precision oncology - general education
    • Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
      OCT 22, 2020 12:05 PM SGT
      Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
      Aaron Tan, PhD
      Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
    • The role of PARPis and HRD testing in advanced ovarian cancer
      OCT 22, 2020 12:25 PM SGT
      The role of PARPis and HRD testing in advanced ovarian cancer
      Natalie Ngoi, MBBS, MMed, MRCP
      Associate Consultant, National University Cancer Institute, Singapore
    • Part 2: Experiences with Oncomine Solutions for clinical research
    • OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
      OCT 22, 2020 1:15 PM SGT
      OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
      Ahwon Lee, MD, PhD
      Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
    • Latest Developments with the Genexus System
      OCT 22, 2020 1:35 PM SGT
      Latest Developments with the Genexus System
      Dr. Jose Luis Costa
      Medical Director, Thermo Fisher Scientific
    • Part 3: Genexus Live Demo
    • LIVE DEMO: The Ion Torrent Genexus System
      OCT 22, 2020 2:10 PM SGT
      LIVE DEMO: The Ion Torrent Genexus System
      Andrew Hutchison
      Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Europe/North America Live Session 2
    • Part 1: NGS in precision oncology - general education
    • NGS for precision oncology in solid tumors: from research to clinical practice
      OCT 22, 2020 3:05 PM CEST
      NGS for precision oncology in solid tumors: from research to clinical practice
      Nicola Normanno, MD
      Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    • Part 2: Experiences with Oncomine Solutions for clinical research
    • Next Generation rEvolution in Myeloid Neoplasms clinical research
      OCT 22, 2020 3:35 PM CEST
      Next Generation rEvolution in Myeloid Neoplasms clinical research
      Giada Rotunno, PhD
      Research Scientist, University of Florence
    • NGS evolution in Solid Tumours, from S5-XL to Genexus
      OCT 22, 2020 4:20 PM CEST
      NGS evolution in Solid Tumours, from S5-XL to Genexus
      Javier Hernandez-Losa, PhD
      Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
    • First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
      OCT 22, 2020 4:40 PM CEST
      First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
      Ines Raineri, MD
      Staff Pathologist, Institute for Pathology medica AG
    • Part 3: Genexus Live Demo
    • LIVE DEMO: The Ion Torrent Genexus System
      OCT 22, 2020 5:15 PM CEST
      LIVE DEMO: The Ion Torrent Genexus System
      Andrew Hutchison
      Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • North America/Australia Live Session 3
    • Part 1: NGS in precision oncology - general education
    • Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
      OCT 22, 2020 12:05 PM PDT
      Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
      Carmen Kletecka, MD, FCAP, FASCP
      Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
    • Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
      OCT 22, 2020 12:25 PM PDT
      Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
      Megan S. Lim, MD, PhD
      Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
    • Part 2: Experiences with Oncomine Solutions for clinical research
    • Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
      OCT 22, 2020 1:15 PM PDT
      Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
      Craig Mackinnon, MD, PhD
      Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
    • Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
      OCT 22, 2020 1:35 PM PDT
      Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
      Jane Bayani, PhD
      Principal Research Scientist, Ontario Institute for Cancer Research
    • Part 3: Genexus Live Demo
    • LIVE DEMO: The Ion Torrent Genexus System
      OCT 22, 2020 2:10 PM PDT
      LIVE DEMO: The Ion Torrent Genexus System
      Andrew Hutchison
      Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
Speakers

  • MODERATOR: Luca Quagliata, PhD
    Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
  • Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
    Biography
      Dr. Bayani is a Principal Research Scientist at the Ontario Institute for Cancer Research in the Department of Diagnostic Development. She obtained her PhD at the University of Toronto in the Department of Laboratory Medicine and Pathobiology. She has an extensive background in molecular pathology and molecular cytogenetics and now leads a number of the genomic translational research projects as part of the senior scientific team in Diagnostic Development. Her focus is on precision medicine approaches for prognostic and predictive biomarkers in early hormone receptor positive breast cancers and in early prostate cancer.
    • Dr. Jose Luis Costa
      Medical Director, Thermo Fisher Scientific
      Biography

        José Luis Costa carried out his undergraduate studies at the University of Porto in Portugal and obtained his Ph.D. degree in Biology at Uppsala University in Sweden. Prior to joining the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) in 2006, he carried out postdoctoral research at the Vrije University Medical Center in Amsterdam, The Netherlands. He was appointed, in 2014, as Affiliated Professor at the Medical Faculty of the University of Porto. In 2020, joined Thermo Fisher Scientific as EMEA Medical Affairs Director part of the Clinical NGS and Oncology Division. Throughout his career he seeks to promote the uptake of Precision Medicine for the benefit of patients through the application of the latest technologies in the diagnosis and the search for precision therapies.

      • Javier Hernandez-Losa, PhD
        Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
        Biography

          Dr. Hernández Losa is Director of Molecular Biology Laboratory in the Department of Pathology from the Vall d´Hebron Hospital in Barcelona. He has trained in Cancer Research, focusing on the signaling and virus detection pathways in FFPE human samples at the Department of Pathology in Hospital Puerta de Hierro (Madrid). After his Ph.D. in Biochemistry and Molecular Biology, he moved to Vall d´Hebron Hospital endorsing extensive experience in drug synergisms in different in vitro models of breast and pancreatic cancer, also in the field of biomarkers, being today one of the reference laboratories in Molecular Pathology. In addition in the last five years, the laboratory has validated by immunohistochemistry more than 12 prognostic and/or predictive markers of cancer. Thanks to these molecular analyzes based on real-time PCR and NGS have contributed to the selection of patients for the different clinical trials carried out at our institution. Dr. Hernández-Losa has been also involved in different technologies validation for mutational analysis of KRAS, NRAS, BRAF, PIK3CA, and EGFR genes in samples from colorectal cancer and NSCLC patients, as well as in exosome samples obtained from primary tumors.

        • Andrew Hutchison
          Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
        • Carmen Kletecka, MD, FCAP, FASCP
          Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
          Biography

            Dr. Kletecka a board certified and fellowship trained Molecular Pathologist. She performed her residency training in anatomic and clinical pathology at Case Western Reserve University Hospitals of Cleveland and fellowship subspecialty training in Molecular Genetic Pathology and Surgical Pathology at TriCore Reference Laboratories and the University of New Mexico Hospital. She currently serves as the Medical Director of the VISN22 Molecular Diagnostics Laboratory in Los Angeles where she and her team implemented molecular oncology testing by next generation sequencing for the VA system.

          • Ahwon Lee, MD, PhD
            Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
            Biography

              Dr. Ahwon Lee is a professor of the college of medicine in the Catholic university of Korea, and a pathologist in Seoul St. Mary’s hospital who works with clinicians to find actionable mutations with various molecular biomarkers. As a pioneer of NGS routine test in Korea, she has set up and implemented comprehensive NGS tests for a solid tumor under the Korean health insurance reimbursement. She has published numbers of textbooks and scientific papers on breast pathology and gynecological oncology. Today she shares her precious experience and perspective with us about OCA Plus test.

            • Megan S. Lim, MD, PhD
              Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
              Biography

                Megan S. Lim, MD, PhD is the Director of the Division of Hematopathology, Hospital of the University of Pennsylvania, Director of the Hematopathology Fellowship Program, and the Director of the Lymphoma Biology Program at the Abramson Cancer Center. She is a Professor within the Department of Pathology and Laboratory Medicine, Dr. Lim received an MD from the University of Calgary and a PhD in Molecular Oncology from the University of Calgary and National Cancer Institute Lab of Pathology jointly. Dr. Lim obtained her Hematopathology fellowship training at the National Cancer Institute after which she assumed a faculty position at the University of Toronto (1998-2000), the University of Utah (2000-2006). the University of Michigan (2006-2015) before moving to the University of Pennsylvania in 2015. Dr. Lim is certified by the American Board of Pathology in Anatomic Pathology, with subspecialty certification in Hematopathology and Molecular Genetic Pathology.  She has held numerous leadership positions and served on training and education committees for the Association of Molecular Pathology and the United States Academy of Pathology. She is a member of the Board of Directors for the United States Academy of Pathology. She is the Vice-Chair of the Non-Hodgkin Lymphoma Disease Committee of the Children’s Oncology Group and participates in integrated translational research in pediatric lymphoma. Her research interests are focused on elucidating mechanisms involved in lymphoma pathogenesis which are supported by the NIH. She has participated and directed numerous CME activities for AMP, ASCP, CAP, and the USCAP.

              • Craig Mackinnon, MD, PhD
                Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
                Biography

                  Alexander “Craig” Mackinnon Jr., M.D., Ph.D., is the inaugural director of the Division of Genomics Diagnostics and Bioinformatics in the Department of Pathology, School of Medicine at the University of Alabama at Birmingham. Mackinnon is leading ongoing efforts to establish the Precision Diagnostic Laboratory at UAB. A board-certified anatomical and molecular genetic pathologist, Mackinnon joined UAB after serving as associate professor in the Department of Pathology at the Medical College of Wisconsin. Mackinnon directed the Clinical and Translational Research Laboratory (CTRL) at MCW, where he provided interpretation related to the pathology of tumor samples. The lab developed multiple Next Generation Sequencing-based panels targeting variants in both DNA and RNA. He has experience designing and validating targeted, custom DNA and RNA sequencing assays. Mackinnon’s lab interpreted a range of tests, from sequencing data to digital quantitative imaging for immunohistochemical analysis. Mackinnon is a member of the College of American Pathologists and the American Society of Clinical Pathology, where he served on the Molecular Pathology Section, Pathologist Recertification Individualized Self-Assessment Examination Committee.

                • Natalie Ngoi, MBBS, MMed, MRCP
                  Associate Consultant, National University Cancer Institute, Singapore
                  Biography

                    Dr Natalie Ngoi a medical oncologist at the National University Cancer Institute, Singapore (NCIS). Her primary clinical and research interests are in gynaecological cancers, genitourinary cancers, and precision oncology. Dr Ngoi graduated from the Yong Loo Lin School of Medicine, National University of Singapore with the degree of MBBS with Honours. She completed her Internal Medicine training at the National University Health System, Singapore and was awarded the Gordon Ransome Gold Medal in Internal Medicine. She undertook specialist training in Medical Oncology at the National University Cancer Institute, Singapore, and qualified as a Medical Oncologist in 2018. Dr Ngoi is currently an Associate Consultant in the gynaecological cancer and genitourinary cancer tumour groups at NCIS, and is an active member of the Gynecologic Cancer Group Singapore (GCGS) and Asia Pacific Gynaecologic Oncology Trials Group (APGOT). She is actively involved in the running of clinical trials at the Developmental Therapeutics Unit (NCIS), and is involved in ovarian cancer research at the Cancer Science Institute of Singapore (CSI).

                  • Nicola Normanno, MD
                    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
                    Biography

                      Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.

                    • Ines Raineri, MD
                      Staff Pathologist, Institute for Pathology medica AG
                      Biography

                        After receiving her MD degree from the University of Zurich, Switzerland, Ines Raineri attended a postgraduate course for basic science at the same university. She then worked as postdoctoral fellow at the Institute for Medical Microbiology of the University of Basel, Switzerland, investigating HIV-promoter-insertions in the human genome. She received fellowships from the Swiss National Foundation, Ciba-Geigy Jubiläumsstiftung, Roche Research Foundation and Holderbank Stiftung to work as postdoctoral fellow at the University of California San Francisco, where she was later hired to work as research assistant geneticist. During her nearly 8 years at UCSF she was involved in generating transgenic cell lines and mice to study oxygen free radical metabolism. After returning to Switzerland, she worked again at the Institute for Medical Microbiology of the University of Basel, establishing knockdown systems to rapidly evaluate gene functions in embryonic stem cells. She then moved on to train as a board-certified pathologist and currently works as a staff pathologist at the Institute for Pathology medica AG in Zurich in molecular pathology, histology and cytology.

                      • Giada Rotunno, PhD
                        Research Scientist, University of Florence
                        Biography

                          Giada Rotunno is a biotechnologist, currently researcher scientist at the University of Florence, Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM) directed by Professor AM Vannucchi. Dr. Rotunno graduated in Medical and Pharmaceutical Biotechnology in 2012 and obtained her PhD degree in Biomedical science in Experimental and Clinical Oncology at the University of Florence in 2015. Her main scientific interests concern hematological disorders with particular focus on myeloproliferative neoplasms (MPN). She is working since 2012 on the study of mutation complexity of chronic and acute myeloid neoplasms, contributing to the refinement of the risk stratification of patients with MPN. In these years, she developed the Next Generation Sequencing (NGS) techniques actually used at CRIMM center. Dr Rotunno published 45 papers on high-impact factor journals including Blood, Leukemia and other peer-reviewed journals on myeloid neoplasms.

                        • Aaron Tan, PhD
                          Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
                          Biography

                            Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current focus is in early phase clinical trials and lung cancer translational research. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018 and ESMO Asia 2019 Merit Awards.

                          C.E. Credits

                          The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                          Help

                          General LabRoots Questions

                          email support@labroots.com  

                          Virtual Events and Webinars

                          Supported Configurations

                          • Operating System Internet Explorer Firefox Chrome Safari
                            Vista IE8+ FF10+ Chrome15+
                            Windows 7 IE8+ FF10+ Chrome15+
                            Windows 8 IE10 FF10+ Chrome15+
                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                          • Cookie settings: session cookies enabled
                          • Browser configuration must have JavaScript enabled
                          • Adobe Flash player 10.2 or later

                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                          Internet Connection

                          • A minimum of 100Kbps is recommended for audio-only events
                          • A minimum of 300Kbps is recommended for speaker on-video events

                          Computer Equipment

                          • Screen Resolution: Minimum 1024x768
                          • Video Card: 65,000 colors minimum
                          • Sound card and speakers (or headphones) for hearing webcast in full format
                          • Audio Card: 16-bit minimum
                          • RAM: 512MB of free RAM

                          Firewall Protocol

                          • HTTP on port 80 or HTTPS on port 443
                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                          Work-At-Home Attendees

                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                          For A Seamless Experience

                          When using a mobile device, FREE Mobile Apps are available:

                          - For viewing Webinars:

                          - For viewing Virtual Events

                          Attendee Guide

                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                          Virtual Event and Webinar Support:

                          Continuing Education (CME/CE) Support

                          Show Resources
                          Attendees
                          • See more